Home › Funds › LOOMIS SAYLES & CO L P › REGN
LOOMIS SAYLES & CO L P position in REGN
REGENERON PHARMACEUTICALS · Health Care
LOOMIS SAYLES & CO L P reported holding 1,716,647 shares of REGN (REGENERON PHARMACEUTICALS) in its Q3 2026 13F filing — a position valued at US$1.30B, representing 1.69% of its reported portfolio and ranking #16 among its reported holdings. LOOMIS SAYLES & CO L P has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How LOOMIS SAYLES & CO L P's REGN position evolved
LOOMIS SAYLES & CO L P first disclosed a stake in REGN in Q3 2023 at 1,232,879 shares (US$1.01B). The position peaked in Q4 2025 at 1,934,326 shares, worth US$1.49B. Across 13 filings, LOOMIS SAYLES & CO L P increased the stake 5 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,716,647 shares valued at US$1.30B — a reduction of -142,525 shares quarter over quarter.. Notable position changes include a 33% increase in Q4 2024 (shares fell 11% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.23M | $1.01B | New |
| Q4 2023 | 1.22M | $1.07B | Reduce |
| Q1 2024 | 1.21M | $1.16B | Reduce |
| Q2 2024 | 1.22M | $1.28B | Add |
| Q3 2024 | 1.18M | $1.24B | Reduce |
| Q4 2024 | 1.58M | $1.12B | Add |
| Q1 2025 | 1.64M | $1.04B | Add |
| Q2 2025 | 1.94M | $1.02B | Add |
| Q3 2025 | 1.98M | $1.11B | Add |
| Q4 2025 | 1.93M | $1.49B | Reduce |
| Q1 2026 | 1.91M | $1.48B | Reduce |
| Q2 2026 | 1.86M | $1.16B | Reduce |
| Q3 2026 | 1.72M | $1.30B | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About REGN and 13F data
REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 28 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), Franklin Resources (US$2.75B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding REGN
- Dodge & Cox 4.87M sh · $3.04B · Q2 2026
- DODGE & COX 4.87M sh · $3.04B · Q2 2026
- Franklin Resources 2.95M sh · $2.75B · Q3 2026
- Nuveen, LLC 1.96M sh · $1.48B · Q3 2026
More on LOOMIS SAYLES & CO L P
FAQ
How long has LOOMIS SAYLES & CO L P held REGN?
LOOMIS SAYLES & CO L P has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is LOOMIS SAYLES & CO L P's current position in REGN?
As of Q3 2026, LOOMIS SAYLES & CO L P holds 1.72M shares of REGN (REGENERON PHARMACEUTICALS), valued at $1.30B, representing 1.69% of its reported portfolio and ranking #16.
Has LOOMIS SAYLES & CO L P been buying or selling REGN?
In the latest 13F filing (Q3 2026), LOOMIS SAYLES & CO L P reduced its position in REGN. The position peaked in Q4 2025 at 1.93M shares.
Which other funds hold REGN?
Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, Franklin Resources, among 28 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.